



Ref: FOIA Reference 2023/24-514

Date: 20th November 2023

Email foi@uhnm.nhs.uk

Dear,

I am writing to acknowledge receipt of your email dated 6th September 2023 requesting information under the Freedom of Information Act (2000) regarding AML and CLL.

As of 1st November 2014 University Hospitals of North Midlands NHS Trust (UHNM) manages two hospital sites – Royal Stoke University Hospital, and County Hospital (Stafford). Therefore the response below is for the two sites combined from that date where appropriate.

Q1 Please see below a Freedom of Information request made by OPEN Health. Please answer the questions with regards to NHS patients, i.e., excluding patients that received treatment as part of clinical trials or private healthcare.

Patients with acute myeloid leukaemia (AML)

1. How many patients with AML, in total, have been treated with the following therapies during the last 6 months, irrespective of start date or line of therapy?

- **Azacitidine monotherapy**
- **Low dose cytarabine (LoDAC) monotherapy**
- **Venetoclax + azacitidine**
- **Venetoclax + LoDAC**
- **Ivosidenib**
- **Intensive chemotherapy-based regimen**
- **Other**

A1 We are unable to provide the information you require in the requested format as to release this data could lead to the identification of the person(s) involved due to the low numbers involved and would breach the Trusts obligations under Data Protection Act 2018. Accordingly, this aspect of your request is exempt from disclosure under the terms of Section 40(2) of the FOI Act. *Personal information*. However as the Trust is committed to openness and transparency we can band the numbers as being <5
This exemption is an absolute exemption and therefore no consideration of the public interest test is needed.

- Azacitidine monotherapy - <5
- Low dose cytarabine (LoDAC) monotherapy - 0
- Venetoclax + azacitidine - 20
- Venetoclax + LoDAC - <5
- Ivosidenib - 0
- Intensive chemotherapy-based regimen - 6
- Other - <5

Q2 How many newly diagnosed patients with AML have started first-line treatment with the following therapies during the last 6 months?

- **Azacitidine monotherapy**
- **Low dose cytarabine (LoDAC) monotherapy**
- **Venetoclax + azacitidine**
- **Venetoclax + LoDAC**
- **Ivosidenib**
- **Intensive chemotherapy-based regimen**
- **Other**

Note: this should only include patients who have started first-line treatment during the 6-month window

A2 We are unable to provide the information you require in the requested format as to release this data could lead to the identification of the person(s) involved due to the low numbers involved and would breach the Trusts obligations under Data Protection Act 2018. Accordingly, this aspect of your request is exempt from disclosure under the terms of Section 40(2) of the FOI Act. *Personal information*. However as the Trust is committed to openness and transparency we can band the numbers as being <5
This exemption is an absolute exemption and therefore no consideration of the public interest test is needed.

- Azacitidine monotherapy - 0
- Low dose cytarabine (LoDAC) monotherapy - 0
- Venetoclax + azacitidine - 13
- Venetoclax + LoDAC - 0
- Ivosidenib - 0
- Intensive chemotherapy-based regimen - 6
- Other – <5

Q3 (a) Of the patients with AML treated with venetoclax (venetoclax + azacitidine or venetoclax + LoDAC) in the last 6 months, how many are approved for treatment via Blueteq?

A3 20

**Q4 Patients with chronic lymphocytic leukaemia (CLL)
How many patients with CLL have received treatment with venetoclax in the past 6 months (including venetoclax monotherapy, venetoclax + rituximab, venetoclax + obinutuzumab or venetoclax + ibrutinib)?**

Note: this should include patients who started treatment prior to the 6-month window

A4 19

Q5 How many patients with CLL who were new to all lines of treatment received venetoclax in the past 6 months (including venetoclax monotherapy, venetoclax + rituximab, venetoclax + obinutuzumab or venetoclax + ibrutinib)?

Note: this should include only patients who have started treatment during the 6-month window

A5 13

*Please note that any individuals identified do not give consent for their personal data to be processed for the purposes of direct marketing.

UHNM NHS Trust is a public sector body and governed by EU law. FOI requestors should note that any new Trust requirements over the EU threshold will be subject to these regulations and will be advertised for open competition accordingly.

Where the Trust owns the copyright in information provided, you may re-use the information in line with the conditions set out in the Open Government Licence v3 which is available at <http://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/>. Where information was created by third parties, you should contact them directly for permission to re-use the information.

An anonymised copy of this request can be found on the Trust's disclosure log, please note that all requests can be found at the following link: <http://www.uhnm.nhs.uk/aboutus/Statutory-Policies-and-Procedures/Pages/Freedom-of-Information-Disclosure-Log.aspx>

This letter confirms the completion of this request. A log of this request and a copy of this letter will be held by the Trust.

If you have any queries related to the response provided please in the first instance contact my office.

Should you have a complaint about the response or the handling of your request, please also contact my office to request a review of this. If having exhausted the Trust's FOIA complaints process you are still not satisfied, you are entitled to approach the Information Commissioner's Office (ICO) and request an assessment of the manner in which the Trust has managed your request.

The Information Commissioner may be contacted at:

Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire SK9 5AF or via www.ico.org.uk.



University Hospitals
of North Midlands
NHS Trust

Yours,

Rachel Montinaro

Data Security and Protection Manager - Records